Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001640334-24-001798
Filing Date
2024-11-27
Accepted
2024-11-27 14:39:04
Documents
8
Period of Report
2025-01-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A lxrp_def14a.htm DEF 14A 558382
2 lxrp_def14aimg15.jpg GRAPHIC 6077
3 lxrp_def14aimg16.jpg GRAPHIC 1372
4 lxrp_def14aimg17.jpg GRAPHIC 1436
5 lxrp_def14aimg18.jpg GRAPHIC 1365
6 lxrp_def14aimg3.jpg GRAPHIC 216246
7 lxrp_def14aimg4.jpg GRAPHIC 20927
8 lxrp_pre14aimg2.jpg GRAPHIC 10530
  Complete submission text file 0001640334-24-001798.txt   915772
Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Filer) CIK: 0001348362 (see all company filings)

EIN.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
Type: DEF 14A | Act: 34 | File No.: 001-39874 | Film No.: 241510204
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)